Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT00335712 Completed - Clinical trials for Type 2 Diabetes Mellitus

Pilot Study of ONO-5129 in Patients With Type 2 Diabetes Mellitus

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of ONO-5129 in patients with type 2 diabetes mellitus.

NCT ID: NCT00334503 Completed - Clinical trials for Type 2 Diabetes Mellitus

Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

NCT ID: NCT00334399 Completed - Clinical trials for Type 2 Diabetes Mellitus

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus treated with Biguanide.

NCT ID: NCT00330330 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Start date: February 2003
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.

NCT ID: NCT00328627 Completed - Clinical trials for Type 2 Diabetes Mellitus

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Start date: May 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.

NCT ID: NCT00328536 Completed - Clinical trials for Type 2 Diabetes Mellitus

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether a 6-week treatment with 4 g Omacor/day improves the baseline and postprandial endothelial function (after a high-fat meal) in patients with type 2 diabetes mellitus.

NCT ID: NCT00324363 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Start date: January 2006
Phase: Phase 3
Study type: Interventional

This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control.

NCT ID: NCT00311818 Completed - Clinical trials for Type 2 Diabetes Mellitus

Insulin Glargine in Type 2 Diabetes Mellitus

Start date: June 2003
Phase: Phase 4
Study type: Interventional

Primary objective: - To compare efficacy of oral antidiabetics (OAD) combination therapy with either HOE901 insulin analogue once daily or Lispro insulin analogue at mealtime in terms of change in HbA1c (baseline to endpoint). Secondary objectives: - To compare the OAD combination therapy with either HOE901 insulin analogue once daily or Lispro insulin analogue at mealtime in terms of efficacy and safety.

NCT ID: NCT00310297 Completed - Clinical trials for Type 2 Diabetes Mellitus

Insulin Glulisine in Type 2 Diabetes Mellitus

Start date: November 2004
Phase: Phase 1
Study type: Interventional

Primary objective: To compare the pharmacodynamics of insulin glulisine and insulin lispro injected subcutaneously before three 500 kcal standard meals during a 12 hour day, in obese subjects with type 2 diabetes. Secondary objectives: - To compare the pharmacokinetics of insulin glulisine and insulin lispro in obese subjects with type 2 diabetes, injected subcutaneously before three standard meals during a 12-hour day. - The safety of insulin glulisine, the relationship of the pharmacodynamics and pharmacokinetics with skin thickness and C-peptide, non-esterified fatty acid, triglyceride and β-hydroxybutyrate levels in these subjects will also be assessed.

NCT ID: NCT00309127 Completed - Clinical trials for Type 2 Diabetes Mellitus

Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy

Start date: May 2003
Phase: N/A
Study type: Interventional

Disease management using a multidisciplinary team to achieve and maintain optimal metabolic and cardiovascular risk factors control in Type 2 diabetic patients with nephropathy reduces the incidence of end stage renal disease (ESRD) and improves clinical outcomes compared to usual clinic-based care